摘要:
The present invention is directed to compositions of matter comprising nucleic acids encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 207 or 208, encoding an anti-CD79b antibody comprising the heavy chain variable domain sequence of SEQ ID NO: 207 and the light chain variable domain sequence of SEQ ID NO: 208, or encoding an anti-CD79b antibody having : (i) a variable light chain comprising a HVR-L1 having the sequence of SEQ ID NO: 194, a HVR-L2 having the sequence of SEQ ID NO: 195, and a HVR-L3 having the sequence of SEQ ID NO: 196 and (ii) a variable light chain comprising a HVR-H1 having the sequence of SEQ ID NO: 202, a HVR-H2 having the sequence of SEQ ID NO: 203, and a HVR-H3 having the sequence of SEQ ID NO: 204, and vectors and host cells thereof.
摘要翻译:本发明涉及包含编码包含SEQ ID NO:207或208的氨基酸序列的多肽的核酸的物质组合物,编码包含SEQ ID NO:207的重链可变结构域序列的抗CD79b抗体和 SEQ ID NO:208的轻链可变结构域序列,或编码抗CD79b抗体,其具有:(i)包含具有SEQ ID NO:194的序列的HVR-L1的可变轻链,具有序列的HVR-L2 具有SEQ ID NO:196的序列的HVR-L3和(ii)包含具有SEQ ID NO:202的序列的HVR-H1的可变轻链,HVR-H2具有SEQ ID NO: SEQ ID NO:203的序列和具有SEQ ID NO:204的序列的HVR-H3,以及其载体和宿主细胞。
摘要:
The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
摘要:
The present invention is directed to anti-CD79b antibody, huMA79b.v28, and compositions of matter thereof useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
摘要:
The present invention is directed to anti-CD79b antibodies with specific hypervariable region sequences in the heavy and light chain variable domains as enumerated in the SEQ ID NOs described herein.
摘要:
The present invention is directed to compositions of matter comprising immunoconjugates comprising an anti-CD79b antibody comprising: (i) an HVR-L1 sequence of KASQSVDYEGDSFLN (SEQ ID NO: 194), (ii) an HVR-L2 sequence of AASNLES (SEQ ID NO: 195), (iii) an HVR-L3 sequence of QQSNEDPLT (SEQ ID NO: 196), (iv) an HVR-H1 sequence of GYTFSSYWIE (SEQ ID NO: 202), (v) an HVR-H2 sequence of GEILPGGGDTNYNEIFKG (SEQ ID NO: 203), and (vi) an HVR-H3 sequence of TRRVPIRLDY (SEQ ID NO: 204) and to methods of using those compositions of matter for the treatment of hematopoietic tumor in mammals.
摘要翻译:本发明涉及包含免疫偶联物的物质组合物,其包含抗CD79b抗体,其包含:(i)KASQSVDYEGDSFLN(SEQ ID NO:194)的HVR-L1序列,(ii)AASNLES的HVR-L2序列(SEQ ID NO: SEQ.NO.209),(iii)QQSNEDPLT(SEQ ID NO:196)的HVR-L3序列,(iv)GYTFSSYWIE(SEQ ID NO:202)的HVR-H1序列,(v) GEILPGGGDTNYNEIFKG(SEQ ID NO:203)和(vi)TRRVPIRLDY(SEQ ID NO:204)的HVR-H3序列以及使用这些物质组合物治疗哺乳动物造血肿瘤的方法。
摘要:
The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
摘要:
The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
摘要:
The present invention is directed to cysteine-engineered anti-CD79b antibody, huMA79b.v28, and compositions of matter thereof useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
摘要:
The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
摘要:
The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.